Page 5 - Access Pathway News Today

TOKYO and CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO:

/PRNewswire/ -- BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that "LEQEMBI® Intravenous Infusion" (200 mg, 500mg, lecanemab)...

STOCKHOLM, Sept. 25, 2023 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai...

STOCKHOLM, Sept. 25, 2023 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai...

STOCKHOLM, Sept. 25, 2023 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai...

Artificial Intelligence (AI) is rapidly penetrating a number of different sectors, including healthcare. The use of AI in mental health has opened up the possibility of new avenues of care, potentially allowing for more efficient diagnosis, treatment and patient care.

By Faith Ashmore, BenzingaTreatment-resistant depression, also referred to as TRD, is a subset of depression that poses significant challenges for clinicians, patients and those closest to patients....

Treatment-resistant depression, also referred to as TRD, is a subset of depression that poses significant challenges for clinicians, patients and those closest to patients. It is characterized by persistent symptoms of depression that do not respond adequately to at least two different standard antidepressant treatments.

LONDON, Sept. 06, 2023 -- COMPASS Pathways plc , a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of...

COMPASS Pathways plc (NASDAQ: CMPS) shared the results from research on the potential of its novel AI technologies to support its proprietary COM